

Bioscience, an independent testing house, used the In-Vitro Kinetic Time-Kill Method to evaluate the antimicrobial properties of one test product (0.05% Chlorhexidine Gluconate) when challenged with several different microorganism species. All testing was performed in accordance with Good Laboratory Practices, as specified in the FDA 21 CFR Part 58.



BIO SCIENCE
LABORATORIES, INC.

Chlorhexidine Gluconate 0.05% in sterile water, USP (99.95%)					
Bacteria	Challenge Suspension* (CFU/ml)	Exposure Time	Post-Exposure Population (CFU/ml)	Log ₁₀ Reduction	Percent Reduction
<i>Achromobacter xylosoxidans</i> (ATCC# 27061) Report# 1605248-201	5.40 x 10 ⁸	1 minute	3.490 x 10 ⁷	1.1896	93.5370%
		5 minutes	3.00 x 10 ⁵	3.2553	99.9444%
		30 minutes	1.0250 x 10 ³	5.7217	99.9998%
<i>Acinetobacter baumannii</i> (ATCC# 19606) Report# 130377-201	1.5950 x 10 ⁹	1 minute	1.3550 x 10 ⁷	2.0709	99.1505%
		5 minutes	3.350 x 10 ⁵	3.6778	99.9790%
		30 minutes	< 1.00 x 10 ³	6.2028	99.9999%
<i>Acinetobacter baumannii</i> (BSLI# 092216Asp1) Report# 1705193-201	2.4604 x 10 ⁷	1 minute	2.7433 x 10 ⁶	0.9658	88.8501%
		5 minutes	1.5817 x 10 ⁴	3.1935	99.9357%
		30 minutes	<5.9233 x 10 ³	5.3079	99.9759%
<i>Acinetobacter baumannii</i> MDR (ATCC# BAA-1605) Report #130377-201	4.250 x 10 ⁹	1 minute	1.1950 x10 ⁸	1.5510	97.1882%
		5 minutes	8.50 x 10 ³	5.6990	99.9998%
		30 minutes	< 1.00 x 10 ³	6.6284	99.9999%
<i>Enterobacter cloacae</i> MDR ¹ (ATCC# BAA-2468) Report# 130377-201	3.80 x 10 ⁹	1 minute	4.550 x 10 ⁵	3.9218	99.9880%
		5 minutes	< 1.00 x 10 ³	6.5798	99.9999%
		30 minutes	< 1.00 x 10 ³	6.5798	99.9999%
<i>Enterococcus faecalis</i> (BSLI# 092216Efs7) Report# 1708328-201	6.6832 x 10 ⁷	1 minute	> 2.9917 x 10 ⁷	0.3495	55.2360%
		5 minutes	9.10 x 10 ⁶	0.8697	86.3838%
		30 minutes	1.8833 x 10 ⁴	3.7130	99.9718%
<i>Enterococcus faecium</i> VRE (BSLI #060613VRE9) Report #1705193-201	3.6139 x 10 ⁷	1 minute	3.0350 x 10 ⁷	0.0764	16.0187%
		5 minutes	1.9517 x 10 ⁷	0.2696	45.9956%
		30 minutes	1.6471 x 10 ⁵	3.1650	99.5443%
<i>Enterococcus faecium</i> VSE (BSLI #112613VSEfm10) Report #1705193-201	4.7525 x 10 ⁷	1 minute	3.8933 x 10 ⁷	0.0870	18.0782%
		5 minutes	1.3201 x 10 ⁷	0.9881	72.2234%
		30 minutes	7.3167 x 10 ³	3.8598	99.9846%
<i>Escherichia coli</i> (ATCC #BAA-2469) ^{1,2,3,4} Report #1605248-201	2.950 x 10 ⁷	1 minute	2.0550 x 10 ⁴	3.1570	99.9303%
		5 minutes	2.50 x 10 ²	5.0719	99.9992%
		30 minutes	<1.00 x 10 ¹	6.4698	99.9999%

* Reference Sections 14 of Study Protocols for the calculations of reductions from the challenge suspensions

1-New Delhi metallo-beta-lactamase (NDM-1) positive

2-*blaKPC* negative by PCR

3-*blaNDM* positive by PCR

4-Carbapenem-resistant (Imipenem and Ertapenem)

MDR = Multi-Drug Resistant

VRE = Vancomycin Resistant *Enterococcus*

VSE = Vancomycin Susceptible *Enterococcus*

Bioscience, an independent testing house, used the In-Vitro Kinetic Time-Kill Method to evaluate the antimicrobial properties of one test product (0.05% Chlorhexidine Gluconate) when challenged with several different microorganism species. All testing was performed in accordance with Good Laboratory Practices, as specified in the FDA 21 CFR Part 58.



BIO SCIENCE
LABORATORIES, INC.

Chlorhexidine Gluconate 0.05% in sterile water, USP (99.95%)					
Bacteria	Challenge Suspension* (CFU/ml)	Exposure Time	Post-Exposure Population (CFU/ml)	Log ₁₀ Reduction	Percent Reduction
<i>Escherichia coli</i> 0157:H7 (ATCC# 43888) Report# 130377-201	2.70 x 10 ⁹	1 minute	2.350 x 10 ⁴	5.0603	99.9991%
		5 minutes	< 1.00 x 10 ³	6.4314	99.9999%
		30 minutes	< 1.00 x 10 ³	6.4314	99.9999%
<i>Escherichia coli</i> (BSLI# 083116Ec2) Report# 1705193-201	1.3366 x 10 ⁷	1 minute	<9.150 x 10 ²	5.3142	99.9931%
		5 minutes	<5.8333 x 10 ¹	5.7292	99.9995%
		30 minutes	<9.00 x 10 ¹	5.6600	99.9993%
<i>Klebsiella pneumoniae</i> (BSLI# 030116Kpn2) Report# 1705193-201	1.0891 x 10 ⁷	1 minute	1.4667 x 10 ²	4.9133	99.9987%
		5 minutes	<1.00 x 10 ¹	6.0371	99.9999%
		30 minutes	<1.00 x 10 ¹	6.0371	99.9999%
<i>Klebsiella pneumoniae pneumoniae</i> (ATCC# BAA-2146) ^{1,2,3,4} Report# 1605248-201	3.60 x 10 ⁷	1 minute	1.10 x 10 ²	5.5149	99.9997%
		5 minutes	<1.00 x 10 ¹	6.5563	99.9999%
		30 minutes	<1.00 x 10 ¹	6.5563	99.9999%
<i>Pseudomonas aeruginosa</i> (BSLI# 083116Pa18) Report# 1708328-201	9.7525 x 10 ⁶	1 minute	<1.00 x 10 ¹	5.9891	99.9999%
		5 minutes	<1.00 x 10 ¹	5.9891	99.9999%
		30 minutes	<1.00 x 10 ¹	5.9891	99.9999%
<i>Staphylococcus aureus</i> MRSA ^{CI} (BSLI# 042511MRSA) Report# 130417-201	1.8850 x 10 ⁹	1 minute	1.0250 x 10 ⁸	1.2646	94.5623%
		3 minutes	5.80 x 10 ⁶	2.5119	99.6923%
		15 minutes	1.1650 x 10 ⁵	4.2090	99.9938%
<i>Staphylococcus aureus</i> MRSA ^{CI} (BSLI# 092211SaMRSA1) Report# 130417-201	2.0050 x 10 ⁹	1 minute	5.80 x 10 ⁸	0.5387	71.0723%
		3 minutes	6.40 x 10 ⁷	1.4959	96.8080%
		15 minutes	3.80 x 10 ⁴	4.7223	99.9981%
<i>Staphylococcus epidermidis</i> (BSLI# 080916Se1) Report# 1705193-201	2.2723 x 10 ⁷	1 minute	1.5650 x 10 ³	4.1861	99.9931%
		5 minutes	<1.00 x 10 ¹	6.3565	99.9999%
		30 minutes	<1.00 x 10 ¹	6.3565	99.9999%

* Reference Sections 14 of Study Protocols for the calculations of reductions from the challenge suspensions

1-New Delhi metallo-beta-lactamase (NDM-1) positive

2-*blaKPC* negative by PCR

3-*blaNDM* positive by PCR

4-Carbapenem-resistant (Imipenem and Ertapenem)

CI- Clinical Isolate

MRSA = Methicillin Resistant *Staphylococcus aureus*

Bioscience, an independent testing house, used the In-Vitro Kinetic Time-Kill Method to evaluate the antimicrobial properties of one test product (0.05% Chlorhexidine Gluconate) when challenged with several different microorganism species. All testing was performed in accordance with Good Laboratory Practices, as specified in the FDA 21 CFR Part 58.



Chlorhexidine Gluconate 0.05% in sterile water, USP (99.95%)					
Bacteria	Challenge Suspension* (CFU/ml)	Exposure Time	Post-Exposure Population (CFU/ml)	Log₁₀ Reduction	Percent Reduction
<i>Staphylococcus epidermidis</i> (BSLI# 092216Se1) Report# 1705193-201	2.0594 x 10 ⁷	1 minute	2.6833 x 10 ²	4.8855	99.9987%
		5 minutes	<1.00 x 10 ¹	6.3137	99.9999%
		30 minutes	<1.00 x 10 ¹	6.3137	99.9999%
<i>Streptococcus pyogenes</i> (BSLI# 092216Spy1) Report# 1705193-201	2.9257 x 10 ⁶	1 minute	8.20 x 10 ⁵	0.5539	71.9725%
		5 minutes	7.7667 x 10 ³	2.5936	99.7345%
		30 minutes	3.250 x 10 ²	4.0327	99.9889%

Chlorhexidine Gluconate 0.05% in sterile water, USP (99.95%)					
Bacteria	Challenge Suspension* (CFU/ml)	Exposure Time	Mean Post-Numbers Control Population (CFU/ml) N=3	Mean Log₁₀ Reduction	Mean Percent Reduction
<i>Propionibacterium acnes**</i> (ATCC# 6919) Report# 140946-201	2.2250 X 10 ⁹	1 minute	2.1033 x 10 ⁷	1.5488	96.6236%
		3 minutes	2.090 x 10 ⁷	2.2543	99.3945%
		30 minutes	2.1417 x 10 ⁷	4.2984	99.9944%

* Reference Sections 14 of Study Protocols for the calculations of reductions from the challenge suspensions

**Testing was based upon ASTM E2783-11, using a numbers control per the method at each time point because of the fastidious nature of *P. acnes*. This avoids the possible attribution of the product efficacy to die-off of the organism due to the length of the exposure time to environmental conditions, allowing for a more accurate and actual assessment of the inoculum level.

Bioscience, an independent testing house, used the In-Vitro Kinetic Time-Kill Method to evaluate the antimicrobial properties of one test product (0.05% Chlorhexidine Gluconate) when challenged with several different microorganism species. All testing was performed in accordance with Good Laboratory Practices, as specified in the FDA 21 CFR Part 58.



BIOSCIENCE
LABORATORIES, INC.

Chlorhexidine Gluconate 0.05% in sterile water, USP (99.95%)					
Fungi	Challenge Suspension* (CFU/ml)	Exposure Time	Post-Exposure Population (CFU/ml)	Log ₁₀ Reduction	Percent Reduction
<i>Aspergillus niger van Tiegham</i> (ATCC# 6275) Report# 130377-201	2.750 x 10 ⁹	10 minutes	3.90 x 10 ⁸	0.8482	85.8182%
		30 minutes	4.20 x 10 ⁸	0.8161	84.7273%
		60 minutes	3.050 x 10 ⁸	0.9550	88.9091%
<i>Candida albicans</i> (ATCC# 10231) Report# 130377-201	4.050 x 10 ⁹	1 minute	7.30 x 10 ⁵	3.7442	99.9820%
		5 minutes	1.650 x 10 ⁴	5.3900	99.9996%
		30 minutes	< 1.00 x 10 ³	6.6075	99.9999%
<i>Candida auris</i> (AR-BANK# 0381) Report# 1605248-201	3.80 x 10 ⁷	1 minute	5.80 x 10 ⁵	1.8164	98.4737%
		5 minutes	1.560 x 10 ³	4.3867	99.9959%
		30 minutes	<1.00 x 10 ¹	6.5798	99.9999%
<i>Candida auris</i> (AR-BANK# 0382) Report# 1605248-201	5.10 x 10 ⁷	1 minute	3.30 x 10 ⁶	1.1891	93.5294%
		5 minutes	1.2050 x 10 ⁵	2.6266	99.7637%
		30 minutes	<1.00 x 10 ¹	6.7076	99.9999%
<i>Candida auris</i> (AR-BANK# 0383) Report# 1605248-201	6.30 x 10 ⁷	1 minute	1.8350 x 10 ⁷	0.5357	70.8730%
		5 minutes	4.250 x 10 ⁴	3.1709	99.9325%
		30 minutes	<1.00 x 10 ¹	6.7993	99.9999%
<i>Candida glabrata</i> (ATCC# 2001) Report# 130377-201	1.1550 x 10 ¹⁰	1 minute	4.030 x 10 ⁹	0.4573	65.1082%
		5 minutes	6.40 x 10 ⁷	2.2564	99.4459%
		30 minutes	< 1.00 x 10 ³	7.0626	99.9999%

Chlorhexidine Gluconate 0.05% in sterile water, USP (99.95%)				
Virus	Exposure Time	TCID ₅₀ (Log ₁₀) Post-Exposure Infectivity	Log ₁₀ Reduction	Percent Reduction
Hepatitis B Virus Surrogate: Duck Hepatitis B Virus (DHBV) Report# 130378-402	1 minute	5.00	1.00	90.00%
	5 minutes	4.75	1.25	94.38%
	30 minutes	4.00	2.00	99.00%
Hepatitis C Virus Surrogate: Bovine Viral Diarrhea Virus (BVDV) Report# 130378-402	1 minute	5.50	0.75	82.22%
	5 minutes	5.00	1.25	94.38%
	30 minutes	4.50	1.75	98.22%
Human Immunodeficiency Virus Type 1 (HIV-1) Report# 130378-402	1 minute	4.25	1.75	98.22%
	5 minutes	3.50	2.50	99.68%
	30 minutes	2.00	4.00	99.99%

* Reference Sections 14 of Study Protocols for the calculations of reductions from the challenge suspensions